Fructose-induced steatosis in mice: Role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells

Laboratory Investigation

Volumn 91, Issue 6, 2011, Pages 885-895

  Kanuri, Giridhar ^a   Spruss, Astrid ^a   Wagnerberger, Sabine ^a   Bischoff, Stephan C ^a   Bergheim, Ina ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

Akt; c Met; fructose; non alcoholic fatty liver disease; PAI 1

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; CD1 ANTIGEN; FRUCTOSE; GAMMA INTERFERON; INTERLEUKIN 15; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; TETRAZOLIUM; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEEDING; FLUID INTAKE; KUPFFER CELL; LIVER INJURY; MICROSOME; MOUSE; NATURAL KILLER CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD1D; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARRIER PROTEINS; CELLS, CULTURED; DNA PRIMERS; FATTY LIVER; FRUCTOSE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; KUPFFER CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79957609993     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.44     Document Type: Article

References (50)

1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923. (Pubitemid 36397405)
2. Ford ES, Li C, Zhao G, et al. Prevalence of the metabolic syndrome among US adolescents using the definition from the International Diabetes Federation. Diabetes Care 2008;31:587-589.
3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428. (Pubitemid 40523737)
4. Zimmet P, Magliano D, Matsuzawa Y, et al. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295-300.
5. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419. (Pubitemid 29258890)
6. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-1719.
7. Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-826. (Pubitemid 39288114)
8. Adams LA, Lymp JF, St SJ, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121. (Pubitemid 41002048)
9. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004;24:3-20. (Pubitemid 38496045)
10. US Department of Agriculture. MyPyramid.gov Website. Washington, DC. http://www.cnpp.usda.gov/Publications/MyPyramid/OriginalFoodGuide Pyramids/FGP/FGPPamphlet.pdf (accessed 1992).
11. Hanover LM, White JS. Manufacturing, composition, and applications of fructose. Am J Clin Nutr 1993;58:724S-732S. (Pubitemid 23319969)
12. Forshee RA, Storey ML, Allison DB, et al. A critical examination of the evidence relating high fructose corn syrup and weight gain. Crit Rev Food Sci Nutr 2007;47:561-582. (Pubitemid 47171597)
13. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138:1452-1455.
14. Assy N, Nasser G, Kamayse I, et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 2008;22:811-816.
15. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007;47:711-717. (Pubitemid 47503432)
16. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008;48: 993-999.
17. Ackerman Z, Oron-Herman M, et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 2005;45:1012-1018. (Pubitemid 40628952)
18. Armutcu F, Coskun O, Gurel A, et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem 2005;38:540-547. (Pubitemid 40693468)
19. Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructoseinduced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008;48:983-992.
20. Jurgens H, Haass W, Castaneda TR, et al. Consuming fructosesweetened beverages increases body adiposity in mice. Obes Res 2005;13:1146-1156.
21. Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009;50:1094-1104.
22. Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006;55: 415-424. (Pubitemid 43268283)
23. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008;49:821-830.
24. Kudo H, Takahara T, Yata Y, et al. Lipopolysaccharide triggered TNFalpha- induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol 2009;51:168-175.
25. Kanuri G, Spruss A, Wagnerberger S, et al. Role of tumor necrosis factor alpha (TNFalpha) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem; published online 27 August 2010. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20801629.
26. Arteel GE. New role of plasminogen activator inhibitor-1 in alcoholinduced liver injury. J Gastroenterol Hepatol 2008;23:S54-S59. (Pubitemid 351389031)
27. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008;16:1394-1399. (Pubitemid 351770539)
28. Alessi MC, Bastelica D, Mavri A, et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003;23:1262-1268. (Pubitemid 36873814)
29. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336-346. (Pubitemid 38174548)
30. Bergheim I, Guo L, Davis MA, et al. Metformin prevents alcoholinduced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology 2006;130:2099-2112. (Pubitemid 43816952)
31. Ye M, Hu D, Tu L, et al. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci 2008;49:497-504.
32. Taher TE, Tjin EP, Beuling EA, et al. c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol 2002;169:3793-3800.
33. Suzuki H, Toyoda M, Horiguchi N, et al. Hepatocyte growth factor protects against Fas-mediated liver apoptosis in transgenic mice. Liver Int 2009;29:1562-1568.
34. Kaser A, Hava DL, Dougan SK, et al. Microsomal triglyceride transfer protein regulates endogenous and exogenous antigen presentation by group 1 CD1molecules. Eur J Immunol 2008;38:2351-2359.
35. Dougan SK, Salas A, Rava P, et al. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J Exp Med 2005;202:529-539. (Pubitemid 41186951)
36. Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 2004;49:1578-1583. (Pubitemid 39335538)
37. Naldini L, Vigna E, Bardelli A, et al. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 1995;270:603-611.
38. Taniyama Y, Morishita R, Nakagami H, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000;102:246-252. (Pubitemid 30451784)
39. Kaibori M, Kwon AH, Oda M, et al. Hepatocyte growth factor stimulates synthesis of lipids and secretion of lipoproteins in rat hepatocytes. Hepatology 1998;27:1354-1361. (Pubitemid 28227864)
40. Bjorkegren J, Beigneux A, Bergo MO, et al. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 2002;277:5476-5483. (Pubitemid 34968597)
41. Balsara RD, Castellino FJ, Ploplis VA. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 2006;281:22527-22536.
42. Brozovic S, Nagaishi T, Yoshida M, et al. CD1d function is regulated by microsomal triglyceride transfer protein. Nat Med 2004;10:535-539. (Pubitemid 38667914)
43. Dougan SK, Rava P, Hussain MM, et al. MTP regulated by an alternate promoter is essential for NKT cell development. J Exp Med 2007;204:533-545. (Pubitemid 46457077)
44. Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005;42:880-885. (Pubitemid 41401126)
45. Li Z, Oben JA, Yang S, et al. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 2004;40:434-441. (Pubitemid 39062861)
46. Yang L, Jhaveri R, Huang J, et al. Endoplasmic reticulum stress, hepatocyte CD1d and NKT cell abnormalities in murine fatty livers. Lab Invest 2007;87:927-937. (Pubitemid 47267812)
47. Kremer M, Thomas E, Milton RJ, et al. Kupffer cell and interleukin-12- dependent loss of natural killer T cells in hepatosteatosis. Hepatology 2010;51:130-141.
48. Li B, Sun R, Wei H, et al. Interleukin-15 prevents concanavalin Ainduced liver injury in mice via NKT cell-dependent mechanism. Hepatology 2006;43:1211-1219. (Pubitemid 43980099)
49. Olson Jr CM, Bates TC, Izadi H, et al. Local production of IFN-gamma by invariant NKT cells modulates acute Lyme carditis. J Immunol 2009;182:3728-3734.
50. Suzuki A, McCall S, Choi SS, et al. Interleukin-15 increases hepatic regenerative activity. J Hepatol 2006;45:410-418. (Pubitemid 44142113)